Development and Scale-Up of an Improved Manufacturing Route to the ATR Inhibitor Ceralasertib-Reference-Cited by-同舟云学术

Development and Scale-Up of an Improved Manufacturing Route to the ATR Inhibitor Ceralasertib

Published:2020-12-15 Issue:1 Volume:25 Page:43-56
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Graham Mark A.¹^ORCID,Askey Hannah¹,Campbell Andrew D.¹,Chan Lai¹,Cooper Katie G.¹,Cui Zhaoshan²,Dalgleish Andrew¹,Dave David¹,Ensor Gareth¹,Galan Espinosa Maria Rita¹,Hamilton Peter¹,Heffernan Claire¹,Jackson Lucinda V.¹,Jing Dajiang²,Jones Martin F.¹,Liu Pengpeng²,Mulholland Keith R.¹,Pervez Mohammed¹,Popadynec Michael¹,Randles Emma¹,Tomasi Simone¹^ORCID,Wang Shenghua²

Affiliation:

1. Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K.

2. Asymchem Laboratories (Tianjin) Co. Ltd., TEDA, Tianjin 300457, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.0c00482

Reference21 articles.

1. Foote, K. M.; Nissink, J. W. M.; Turner, P. Morpholino pyrimidines and their use in therapy. WO 2011154737 A1, 2011.

2. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent